george nakayama - pharma delegatespharmadelegates.jp/wp-content/uploads/2016/09/20160921...
TRANSCRIPT
George Nakayama President and CEO Daiichi Sankyo Co., Ltd.
Pharma Delegates Luncheon Meeting, Tokyo September 21, 2016
Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi
Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements
were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future
forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results
of Daiichi Sankyo may diverge materially from Daiichi Sankyo’s outlook or the content of this material. Furthermore, there is
no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts,
Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this
material onward.
Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to
guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this
material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo
Group that is described within this material has been compiled or cited using publicly available information or other information,
and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc.
of such information, and does not guarantee the accuracy thereof.
The information described in this material may be changed hereafter without notice. Accordingly, this material or the
information described herein should be used at your own judgment, together with any other information you may otherwise
obtain.
This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States,
Japan or elsewhere.
This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.
Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including
without limitation damages related to the use of erroneous information.
1
Brief History of Daiichi Sankyo Current Status 2025 Vision 5-Year Business Plan and Beyond Growth beyond FY2017 LOE Edoxaban Japan Business Pain Franchise
Establish Foundation of Oncology Beyond Horizon: Cell Therapy
Conclusion
Agenda
2
Brief History of Daiichi Sankyo Current Status 2025 Vision 5-Year Business Plan and Beyond Growth beyond FY2017 LOE Edoxaban Japan Business Pain Franchise
Establish Foundation of Oncology Beyond Horizon: Cell Therapy
Conclusion
Agenda
3
Daiichi Sankyo, an Innovative Pharmaceutical Company Since Its Founding
Daiichi Sankyo
Edoxaban
Olmesartan Pravastatin
Levofloxacin
Sankyo Daiichi
Pharmaceutical
Dr. Jokichi Takamine Dr. Katsuzaemon Keimatsu
2007
1899 1915
4
Brief History of Daiichi Sankyo Current Status 2025 Vision 5-Year Business Plan and Beyond Growth beyond FY2017 LOE Edoxaban Japan Business Pain Franchise
Establish Foundation of Oncology Beyond Horizon: Cell Therapy
Conclusion
Agenda
5
Daiichi Sankyo Global Sales FY2015 Revenue: JPY 986 Billion
28%
58% 8%
Japan
Europe
North America
Other areas
Geographies
9%
10%
41%
9%
Cardiovascular-metabolic
Gastro-intestinal
Blood
Musculoskeletal
Therapeutic Areas*
6%
5% 4%
21%
Systemic Anti-infectives Central Nervous System
Oncology & Immunomodulators
*Source: EvaluatePharma® 2015 Sales
1%
Other RX/OTC products
6
6 42 88
128 147
173 33
39 40
45 16
10
121
167
209
268
FY2012 FY2013 FY2014 FY2015
(USD Million) Currency rate : JPY/USD=120
anti-hypertension
Olmesartan (Benicar® : US Olmetec® : JP, EU)
antiplatelet
Prasugrel (Effient® : US Efient® : JP, EU)
anticoagulant
Edoxaban (Savaysa® : US Lixiana® : JP, EU)
Not disclose
Not disclose
Major Global Products
793 813 789 768
790 936 888 930
401 547 544 491 173 206 225 180 2,157
2,502 2,446 2,368
FY2012 FY2013 FY2014 FY2015
OthersEUUSJapan
30
108
6
3 13
3 3
36
124
FY2012 FY2013 FY2014 FY2015FY2012 FY2013 FY2014 FY2015
Others EU US Japan
124
7
Lixiana®
(anti-coagulant)
Ranmark®
(bone metastasis)
Effient®
(antiplatelet)
Canaglu®
(anti-diabetic)
Memary®
(anti-Alzheimer)
Nexium®
(anti-ulcer)
Tenelia®
(anti-diabetic)
Pralia®
(osteoporosis)
Sales Pipeline Success
(anti-cancer) (antiplatelet)
Japan (anti-coagulant)
Global MovantikTM
(opioid induced constipation)
: acquired or in-licensed products 8
as of March 2016
16,000 Worldwide Employees
- Germany - UK - Ireland - France - Spain - Portugal - Italy - Netherlands - Belgium - Austria - Switzerland - Turkey
- China - South Korea - Taiwan - Hong Kong - Thailand - India - Brazil
- Venezuela
EU 2000
Asia 1900
Latin America 500
US 2300
Japan 8600
Our Global Prominence
9
FY2017 LOE
(USD Million) *Currency rate: JPY/USD=110
anti-hypertension
Olmesartan (Benicar: US Olmetec: JP, EU)
Olmesartan LOE US in October 2016 EU/Japan early 2017
719 693 671 618
857 700 661 382
376 309 281
218
224 245 196
172
2,176 1,947 1,809
1,390
FY2013 FY2014 FY2015 FY2016
OthersEUUSJapan
(estimate)
10
Brief History of Daiichi Sankyo Current Status 2025 Vision 5-Year Business Plan and Beyond Growth beyond FY2017 LOE Edoxaban Japan Business Pain Franchise
Establish Foundation of Oncology Beyond Horizon: Cell Therapy
Agenda
11
Management Policy Transformation
• CVM area • PCP focus • Global products • In-house • Sales volume
Until 2015
12
Management Policy Transformation
• CVM area • PCP focus • Global products • In-house • Sales volume
Until 2015
2025 Vision
• Oncology area • Specialty area • Regional value • Alliance • Sustainable profit
growth
13
Management Policy Transformation
• CVM area • PCP focus • Global products • In-house • Sales volume
Until 2015
2025 Vision
2016-2020 5-Year Business
Plan
Transformation toward 2025 Vision
• Oncology area • Specialty area • Regional value • Alliance • Sustainable profit
growth
14
Brief History of Daiichi Sankyo Current Status 2025 Vision 5-Year Business Plan and Beyond Growth beyond FY2017 LOE Edoxaban Japan Business Pain Franchise
Establish Foundation of Oncology Beyond Horizon: Cell Therapy
Agenda
15
Growth beyond FY2017 LOE Edoxaban Japan Business Pain Franchise
16
Growth beyond FY2017 LOE Edoxaban (Lixiana®, Savaysa®) Japan Business Pain Franchise
17
Edoxaban: Japan
Latest market share reached: 13.5% (Apr. 2016 ~ Jun. 2016)
0
10
20
30
40
50
FY2014Q2 FY2014Q3 FY2014Q4 FY2015Q1 FY2015Q2 FY2015Q3 FY2015Q4 FY2016Q1
LixianaProduct AProduct BProduct C
Market Share: 13.5%
(%)
©2016 IMS Health Calculated based on JPM 2014. Oct.-2016. Jun. Reprinted with permission 18
101
214
431
749
0
200
400
600
800
1,000
1,200
2011 2012 2013 2014 2015
Growth of Global DOAC* Market
120 JPY/USD
1,100 2% 5% 11% 18%
0%
20%
40%
60%
80%
100%
2011 2012 2013 2014 2015
25%
DOAC VKA (vitamin K antagonists)
VKAs vs. DOACs - Volume (DOT) (Bn JPY)
*DOAC : Direct Oral Anticoagulant , same meaning as NOAC (novel oral anticoagulant) ©2016 IMSHealth Calculated based on IMS MIDAS Sales Data 2011-2015 Reprinted with permission
DOAC market trend
19
Expand as Growth Driver for Mid- to Long Term
Execute launch strategy Appeal product profile continuously Generate new evidence to strengthen product
• Ensure-AF, Hokusai-VTE Cancer etc. • ENTA Registries
14.7
69.0
Global strategies Over 120 Bn JPY (1 Bn USD) in FY2020
Regional strategies Japan
Utilize product profile and fine-tuned sales capabilities with high quality
Nurture into Japan’s No. 1 DOAC
US* Acquire prescriptions through specifically targeted promotions Improve market access
Europe Conduct promotion across Europe through
collaboration with MSD*
ASCA and other regions Realize early approval and launch in all countries of operation Conduct promotion through collaboration with best partners
*MSD: Merck Sharp and Dohme Europe Subsidiary of Merck & Co., Inc.
* Conservative assumption that insurance reimbursement status in United States will remain unchanged
FY2015 FY2017 FY2020
(Bn JPY)
Others Japan/ Europe
20
FY2017 LOE
Olmesartan Benicar, Olmetec etc
Prasugrel Effient, Efient
Levofloxacin
Pravastatin
FY2007 FY2012 FY2016 FY2020
Edoxaban Lixiana, Savaysa
Oncology etc.
21
22
Growth beyond FY2017 LOE Edoxaban Japan Business Pain Franchise
Japan: 4 Businesses
Innovative about 440Bn JPY
Daiichi Sankyo
OTC about 53Bn JPY
Daiichi Sankyo Healthcare
Vaccine about 36Bn JPY
Kitasato Daiichi Sankyo Vaccine
Japan Vaccine
Generic about 18Bn JPY
Daiichi Sankyo Espha
23
Japan: Major Products
73 92
112 118
2013 2014 2015 2016
29 66
113 145
2013 2014 2015 2016
302 334 385 463
2013 2014 2015 2016
For No.1 market share company in Japan
(USD Million) *Currency rate: JPY/USD=110
anti-ulcer (PPI) Nexium
treatment for alzheimer’s disease Memary (Namenda)
treatment for osteoporosis Pralia (Prolia)
treatment for bone metastases Ranmark (Xgeva)
(estimate) (estimate)
492 630
749 727
2013 2014 2015 2016
(estimate) 2013 2014 2015 2016
(estimate) 2013 2014 2015 2016
(estimate) 2013 2014 2015 2016
24
Grow Major Products in Japan
170
243 Product strategies
Nexium (anti-ulcer; Proton Pump Inhibitor) Maintain No. 1 share by establishing position as “first choice” drug for GERD* treatment
Memary (treatment for Alzheimer’s Disease) Standardize combination therapy with ChE** inhibitor for the treatment of moderate-to-severe AD*** by provision of clinical evidence
Pralia (treatment for osteoporosis) Expand market penetration by promoting high evaluation received by guideline Further growth by additional indication of rheumatoid arthritis
Ranmark (treatment for bone metastasis ) Maintain position as standard of care for treating bone metastasis of cancer Further growth by additional indication of breast cancer
Effient (antiplatelet) Maintain dominating No. 1 share in heart area by promoting dosage ideal for Japanese Lead next generation of antiplatelet treatment in Japan by additional indication of brain area
Teneria (treatment for type 2 diabetes) Appeal efficacy and ease of use for elderly people and patients with renal impairment to aim for first-line treatment for diabetes and expand market share
Maintain growth by existing products and additional indications
Red:additional indication (Planned)
226
*GERD: Gastroesophageal Reflux Disease **ChE: Cholinesterase ***AD: Alzheimer‘s disease
FY2015 FY2017 FY2020
(Bn JPY)
Total of 6 products in right column (excl. Lixiana), Including the impact of mandated price revisions 25
New Products and Additional Indications
New product - Lacosamide (Epilepsy) - VN-100 (Seasonal flu vaccine)
New product - Hydromorphone (Cancer pain) - Etanercept BS (Rheumatoid arthritis) - VN-0107/MEDI3250 (Seasonal flu
vaccine as a nasal spray) Additional indication - Prasugrel (Ischemic stroke) - Denosumab (Rheumatoid arthritis)
New product - Mirogabalin (DPNP, PHN)*
New product - CS-3150 (Hypertension) - Quizartinib (Acute myeloid leukemia) - VN-0105 (DPT-IPV/Hib vaccine)
New product - VN-0102 (Measles-Mumps-Rubella
vaccine) Additional indication - Denosumab (Breast cancer adjuvant)
Seamless launch of new products and additional indications
FY2016 FY2017 FY2018 FY2019 FY2020
*DPNP: Diabetic peripheral neuropathic pain PHN : Postherpetic neuralgia
New product - Nine Bio-Similar Products (from Amgen)
26
Growth of Japan
Business
Fine-tuned sales
capabilities
Acquire valuable new
products
Sales growth of acquired
products
Process for Sustainable Growth
Realize sustainable growth by leveraging No.1 sales capabilities of leading company in Japan
Top class sales capabilities in quantity and
quality
No.1 market share
No.1 evaluation
Continuous launch & sales growth of own
products
27
Growth beyond FY2017 LOE Edoxaban Japan Business Pain Franchise
28
25%
18%
23%
5%
5%
12%
3% 5%
2%
* Immediate-Release Opioid, ** Extended-Release Opioid † Pain management use only
Source: Internal analysis based on Symphony Health Solutions, PHAST Integrated Monthly, 2007-2015 and Encuity 2007-2015
Large, Growing Market with Diverse Segments
U.S. Pain Market Gross Sales (US$ Billion)
2015: $28 Billion ‘07-’15 CAGR 6.6%
330~ Million TRx
Anesthetics 1%
ERO**
Non-narcotic analgesics
Anti-epileptics†
Pregabalin Anti-migraine
TCAs† SNRIs† 1%
IRO* >30 days
Mirogabalin
CL-108
Movantik
Acute IRO*
(<15 days)
Other Non-Acute IRO* (>15 days & <30 days)
U.S. Pain Market Holds Great Opportunity
9 10 11 11 12 11 11 13 13
17 19 19 20 21 22 23
26 28
2007 2008 2009 2010 2011 2012 2013 2014 2015
OthersOpioids
29
Movantik
First once-daily oral product FDA approved for the treatment
of opioid-induced constipation (OIC) for adults with chronic
non-cancer pain
Co-promotion with AstraZeneca from FY15 and 1.3 billion
yen revenue up to December 2015
While the reported occurrence of OIC varies, it affects
roughly 40% of patients in clinical trials who were taking
opioids for chronic pain
30
Novel, opioid-containing formulation for the management of
pain severe enough to require an opioid analgesic while
preventing or reducing the associated opioid-induced
nausea and vomiting (OINV) when alternative treatments for
pain are inadequate
Reports in the literature suggest approximately 40% of
patients experience OINV, and the incidence may be higher
in clinical practice
Met primary endpoints in two pivotal Ph3 studies
CL-108
Hydrocodone 7.5 mg / Acetaminophen 325 mg +
Promethazine 12.5 mg (Rapid release)
31
Mirogabalin
If approved, mirogabalin may provide a new therapeutic
option for patients in the US with pain associated with
fibromyalgia
The α2δ-ligand Market as large as 64MM Prescriptions
in 2015
Ph3 control drug: pregabalin - U.S. Net sales reached
$2.7 Billion in 2015
Pain associated with fibromyalgia has a substantial
impact on the 5 to 7 million adults – the majority of
whom are women - in the US with the condition.
Top line results anticipated 1H CY2017 Sources: Sales reported by Pfizer in Q4-2015 earnings; EvaluatePharma® 32
Rapid Growth in Pain Franchise
FY2015 FY2017 FY2020 Mirogabalin
KSF & main tactics
Movantik Raise awareness of burden of OIC Inspire a conversation about OIC Deliver affordable access
CL-108: Targeted launch in FY 2017 Raise HCPs’ OINV awareness Engage the medical community
Mirogabalin: Targeted launch in FY 2019 Differentiate from pregabalin based on Ph3
results
Movantik, CL-108
>100 Bn JPY business in FY2020
33
Brief History of Daiichi Sankyo Current Status 2025 Vision 5-Year Business Plan and Beyond Growth beyond FY2017 LOE Edoxaban Japan Business Pain Franchise
Establish Foundation of Oncology Beyond Horizon: Cell Therapy
Conclusion
34
Agenda
DS-3032
NME of clinical pipeline
Phase III
Phase II
Phase I
efatutazone (CS-7017)
tigatuzumab (CS-1008)
nimotuzumab (DE-766)
tivantinib (ARQ 197)
U3-1287
efatutazone (CS-7017)
nimotuzumab (DE-766)
tigatuzumab (CS-1008)
denosumab (AMG162)
NDA
3
6
• Maximizing internal assets
• Acquisition of external assets
FY2006 FY2008 FY2010 FY2012 FY2014
Launch
PLX3397
U3-1565
vemurafenib (PLX4032)
tivantinib (ARQ 197)
U3-1287
efatutazone (CS-7017)
nimotuzumab (DE-766)
tigatuzumab (CS-1008)
denosumab (AMG162)
DS-2248
PLX3397
DS-7423
vemurafenib (PLX4032)
tivantinib (ARQ 197)
U3-1287
efatutazone (CS-7017)
nimotuzumab (DE-766)
tigatuzumab (CS-1008)
denosumab (AMG162)
DS-2248
U3-1565
DS-3078
ARQ 092
U3-1287
vemurafenib (PLX4032)
tivantinib (ARQ 197)
nimotuzumab (DE-766)
denosumab (AMG162)
DS-7423
DS-3078
DS-6051
13
10
DS-8895
DS-5573
DS-3032
DS-8273
U3-1565
17
FY2016
PLX9486
vemurafenib (PLX4032)
tivantinib (ARQ 197)
patriumab (U3-1287)
nimotuzumab (DE-766)
denosumab (AMG162)
PLX51107
PLX8394
DS-6051
DS-8895
DS-5573
DS-8273
U3-1784
21
quizartinib (AC220)
pexidartinib (PLX3397)
DS-8201
Steady growth of Oncology Pipeline
PLX7486
DS-1123
DS-3201
PLX73086/AC708
PLX3397
PLX7486
PLX8394 35
quizartinib (AC220)
Multi-category of Cancer Targeted Therapy
Gene Gene Mutation
Immune cell
Gene Fusion ROS1 NTRK
BRAF FLT3 KIT
EZH1/2 IDH MET
CSF1R HER3 EGFR
MDM2 FGFR4 BRD4 TBD
Gene Amplification/ Overexpression
Cancer cell
Suppression
CSF1R B7-H3* EPHA2* FGFR2*
Activation
Activation
HER2-ADC TBD
New modality
Immune suppression
Preclinical and clinical projects
*ADCC
36
Oncology Business Expansion
Late-stage development TLR NDA
• quizartinib • tivantinib • pexidartinib • patritumab
2015 2017 2020 2025
approval
• DS-8201 • DS-3201 • DS-3032 • DS-6051
Late-stage development TLR NDA
Early-stage development
approval
Innovative
technology etc.
New in-license
Late-stage development
Late-stage development
approval
Pre-clinical
Early-stage development
• vemurafenib • denosumab
Approx. 300.0 Bn JPY
40.0 Bn JPY
Contribution to Revenue
(Image) 37
Glo
bal R
&D
Uni
t R&D Planning
Project Management
Development Other TAs Oncology
Biologics New modality Anti-body
Research Other TAs Oncology
Plexxikon
Venture Science Labs.(VSL)
Asubio
Accelerate Oncology R&D by New R&D Organization
<Global Structure - before April 2016>
38
Accelerate Oncology R&D by New R&D Organization
<Global Structure – as of April 2016> G
loba
l R&
D U
nit
R&D Planning & Management
Project Management
Oncology R&D Unit
Biologics & Immuno-Oncology Labs.
Oncology Labs.
Oncology Clinical Development
Development Function (excl.
Oncology)
Research Technology Function
Research Function (excl. Oncology)
Pain & Neuroscience Labs.
End-Organ Disease Labs.
Rare Diseases & LCM Labs.
Cell Therapy Labs VSL
Asubio
Plexxikon 39
Global Head, Oncology R&D, Antoine Yver
+ Yver A, Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development Annals Oncology April 2016 (on line)
• Former Pediatrician Oncologist, academic faculty Paris, France
• Former Head, Oncology Global Medicines Development at AstraZeneca (2009-2016)
• 26 years pharma experience in global R&D, including early & late phase development and licensing
• Global clinical leader for 12 marketing applications in oncology, 4 new drugs
• In addition, in 2015: olaparib (PARPi), osimertinib (3rd-G mut-EGFRi T790M)+
• Multinational line management experience for development functions, including Japan R&D and China R&D
40
Target Therapeutic Area
Pain
• Generate drugs for pain complementing MOA of current development pipeline
Continuously generate innovative medicine changing Standard of Care
Oncology(incl. Immuno-Oncology) Generate molecular target drugs with potential
to cure or prolong life significantly by mono therapy or combination
CNS* diseases • Generate drugs for
neurodegenerative disease through collaborative research with UCSF
Heart Kidney diseases • Utilize accumulated
knowledge
• Utilize collaborative research with Sanford Burnham
Rare diseases • Optimize modality,
such as nucleic acid, antibody and small molecule
Partnering, Open Innovation Translational Research
New horizon Area
Primary Focused Area
41
Brief History of Daiichi Sankyo Current Status 2025 Vision 5-Year Business Plan and Beyond Growth beyond FY2017 LOE Edoxaban Japan Business Pain Franchise
Establish Foundation of Oncology Beyond Horizon: Cell Therapy
Conclusion
Agenda
42
Accelerate Cell Therapy Research by New R&D Organization
<Global Structure – as of April 2016> G
loba
l R&
D U
nit
R&D Planning & Management
Project Management
Oncology R&D Unit
Development Function
Research Technology Function
Research Function
Pain & Neuroscience Labs.
End-Organ Disease Labs.
Rare Diseases & LCM Labs.
Cell Therapy Labs. VSL
Asubio Regenerative Research
Plexxikon 43
Realize Clinical Application of Innovative Technology: Cell Therapy
Explore seeds utilizing alliances and move them forward to commercialization quickly
• Launch open innovation research to develop the new capillary stem cells (“CapSCs”) discovered by Jun-ichi Kawabe, a professor of Asahikawa Medical University, into a cell source for regenerative medicine and cell therapy
• License agreement with UK-based Cell Therapy Ltd. (currently Celixir) for an exclusive license in Japan to develop and market Heartcel™, a immune-modulatory progenitor (iMP) cell, therapeutic agent for ischemic heart failure
44
Brief History of Daiichi Sankyo Current Status 2025 Vision 5-Year Business Plan and Beyond Growth beyond FY2017 LOE Edoxaban Japan Business Pain Franchise
Establish Foundation of Oncology Beyond Horizon : Cell Therapy
Conclusion
Agenda
45
Investment for future growth
Investment Policy for Future Growth
Highest priority investment: Oncology
R&D expenses Approx. 900 Bn JPY
Business development investments
Approx. 500 Bn JPY
Japan Business
Pain Franchise 46
Recent Partnerships and Acquisitions
47
WHO WHEN AREA HIGHLIGHTS
2011 Global Oncology Therapeutic research areas include oncology, CNS and autoimmune disorders, and neuroinflammatory and cardiorenal diseases
2014 Global Oncology
Now fully integrated into Daiich Sankyo, "Ambit was focused on the discovery and development of medicines to treat unmet medical needs in oncology by inhibiting enzymes that are important drivers for those diseases. The lead drug candidate, quizartinib, is currently in phase 3 clinical trials among patients with a specific type of acute myeloid leukemia (AML).
2016 Japan Market Oncology
Commercialize nine biosimilars in Japan, including biosimilars of adalimumab, bevacizumab and trastuzumab.
2014 Japan Market Co-commerciallization agreement in Japan for Lacosamide(brand name “Vimpat®” for epilepsy.
2014 Pain Franchise
Co-development and co-promotion of CL-108, an investigational potential treatment for moderate to severe acute pain, while reducing the occurrence of OINV, the nausea and vomiting that can often accompany the use of opioids
2015 Pain Franchise
A co-commercialization agreement for a medication indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain
FY2020 Financial Targets
FY2015 (Forecast)
FY2017 (Target)
FY2020 (Target)
Revenue (Bn JPY) 980 940 1,100
Operating Profit (Bn JPY) 130 100 165
Assumption Exchange Rate: 1USD=120JPY, 1EUR=130JPY
ROE: 8% or more (FY2020)
Total return ratio: 100% or more (during 5YBP)
Annual ordinary dividends: more than 70 JPY (during 5YBP)
48
• CVM area • PCP focus • Global products • In-house • Sales volume
Until 2015
2025 Vision
Global Pharma Innovator with Competitive Advantage in Oncology
To have Specialty area business centered on Oncology business as the core business
To have enriched regional value products aligned with regional market
To have innovative products and pipeline changing Standard of Care
To realize shareholders’ value through highly efficient management
2016-2020 5-Year Business
Plan
Transformation toward 2025 Vision
49
Thank you for your attention